Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 3/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24678191 | 0.86 | KDM4E (0.34) | MMP3EPHX1MMP9FOLH1SIRT6 | |
| SCHEMBL22799575 | 0.86 | CYP2C19 (0.39) | MMP3MMP9FOLH1SIRT6SIRT1 | |
| SCHEMBL24703969 | 0.86 | KDM4E (0.34) | MMP3EPHX1MMP9FOLH1SIRT6 | |
| SCHEMBL26231094 | 0.84 | KISS1R (0.41) | KISS1REPHX1CPB2FOLH1KDM4A | |
| SCHEMBL13468552 | 0.84 | KISS1R (0.41) | KISS1REPHX1CPB2FOLH1KDM4A | |
| SCHEMBL18180482 | 0.82 | KISS1R (0.43) | KISS1RMMP3EPHX1MMP9CPB2 | |
| SCHEMBL26743889 | 0.82 | FOLH1 (0.43) | KISS1REPHX1CPB2FOLH1KDM4A | |
| SCHEMBL18180490 | 0.82 | KISS1R (0.43) | KISS1RMMP3EPHX1MMP9CPB2 | |
| SCHEMBL22800674 | 0.82 | SIRT6 (0.37) | EPHX1FOLH1SIRT6SIRT1 | |
| SCHEMBL22803421 | 0.82 | POLB (0.35) | MMP3MMP9FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | SARS1, MMAB, PAM | KISS1R 1161/4885MMP3 1771/4885EPHX1 1493/4885 |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | DCK, PAICS, SAMHD1 | KISS1R 1524/4885MMP3 4227/4885EPHX1 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.